Skip to main content
Top
Published in: European Journal of Clinical Microbiology & Infectious Diseases 2/2024

02-12-2023 | Cefepime | Original Article

Deciphering mechanisms affecting cefepime-taniborbactam in vitro activity in carbapenemase-producing Enterobacterales and carbapenem-resistant Pseudomonas spp. isolates recovered during a surveillance study in Spain

Authors: Marta Hernández-García, María García-Castillo, Marta Nieto-Torres, Germán Bou, Alain Ocampo-Sosa, Cristina Pitart, Irene Gracia-Ahufinger, Xavier Mulet, Álvaro Pascual, Nuria Tormo, Antonio Oliver, Patricia Ruiz-Garbajosa, Rafael Cantón

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 2/2024

Login to get access

Abstract

Purpose

To characterize the resistance mechanisms affecting the cefepime-taniborbactam combination in a collection of carbapenemase-producing Enterobacterales (CPE) and carbapenem-resistant Pseudomonas spp. (predominantly P. aeruginosa; CRPA) clinical isolates.

Methods

CPE (n = 247) and CRPA (n = 170) isolates were prospectively collected from patients admitted to 8 Spanish hospitals. Susceptibility to cefepime-taniborbactam and comparators was determined by broth microdilution. Cefepime-taniborbactam was the most active agent, inhibiting 97.6% of CPE and 67.1% of CRPA (MICs ≤ 8/4 mg/L). All isolates with cefepime-taniborbactam MIC > 8/4 mg/L (5 CPE and 52 CRPA) and a subset with MIC ≤ 8/4 mg/L (23 CPE and 24 CRPA) were characterized by whole genome sequencing.

Results

A reduced cefepime-taniborbactam activity was found in two KPC-ST307-Klebsiella pneumoniae isolates with altered porins [KPC-62-K. pneumoniae (OmpA, OmpR/EnvZ), KPC-150-K. pneumoniae (OmpK35, OmpK36)] and one each ST133-VIM-1-Enterobacter hormaechei with altered OmpD, OmpR, and OmpC; IMP-8-ST24-Enterobacter asburiae; and NDM-5-Escherichia coli with an YRIN-inserted PBP3 and a mutated PBP2. Among the P. aeruginosa (68/76), elevated cefepime-taniborbactam MICs were mostly associated with GES-5-ST235, OXA-2+VIM-2-ST235, and OXA-2+VIM-20-ST175 isolates also carrying mutations in PBP3, efflux pump (mexR, mexZ) and AmpC (mpl) regulators, and non-carbapenemase-ST175 isolates with AmpD-T139M and PBP3-R504C mutations. Overall, accumulation of these mutations was frequently detected among non-carbapenemase producers.

Conclusions

The reduced cefepime-taniborbactam activity among the minority of isolates with elevated cefepime-taniborbactam MICs is not only due to IMP carbapenemases but also to the accumulation of multiple resistance mechanisms, including PBP and porin mutations in CPE and chromosomal mutations leading to efflux pumps up-regulation, AmpC overexpression, and PBP modifications in P. aeruginosa.
Appendix
Available only for authorised users
Literature
7.
go back to reference Hamrick JC, Docquier J-D, Uehara T, Myers CL, Six DA, Chatwin CL et al (2020) VNRX-5133 (Taniborbactam), a broad-spectrum inhibitor of serine-and metallo-lactamases, restores activity of cefepime in Enterobacterales and Pseudomonas aeruginosa. Antimicrob Agents Chemother 64:e01963–e01919CrossRefPubMedPubMedCentral Hamrick JC, Docquier J-D, Uehara T, Myers CL, Six DA, Chatwin CL et al (2020) VNRX-5133 (Taniborbactam), a broad-spectrum inhibitor of serine-and metallo-lactamases, restores activity of cefepime in Enterobacterales and Pseudomonas aeruginosa. Antimicrob Agents Chemother 64:e01963–e01919CrossRefPubMedPubMedCentral
9.
go back to reference Hernández-García M, García-Castillo M, Ruiz-Garbajosa P, Bou G, Siller-Ruiz M, Pitart C, Gracia-Ahufinger I et al (2022) In vitro activity of cefepime-taniborbactam against carbapenemase-producing Enterobacterales and Pseudomonas aeruginosa isolates recovered in Spain. Antimicrob Agents Chemother 66(3):e0216121. https://doi.org/10.1128/aac.02161-21 Hernández-García M, García-Castillo M, Ruiz-Garbajosa P, Bou G, Siller-Ruiz M, Pitart C, Gracia-Ahufinger I et al (2022) In vitro activity of cefepime-taniborbactam against carbapenemase-producing Enterobacterales and Pseudomonas aeruginosa isolates recovered in Spain. Antimicrob Agents Chemother 66(3):e0216121. https://​doi.​org/​10.​1128/​aac.​02161-21
10.
go back to reference Hernández-García M, García-Castillo M, García-Fernández S, Melo-Cristino J, Pinto MF, Goncalves E et al (2020) Distinct epidemiology and resistance mechanisms affecting ceftolozane / tazobactam in Pseudomonas aeruginosa isolates recovered from ICU patients in Spain and Portugal depicted by WGS. J Antimicrob Chemother 1–10. https://doi.org/10.1093/jac/dkaa430 Hernández-García M, García-Castillo M, García-Fernández S, Melo-Cristino J, Pinto MF, Goncalves E et al (2020) Distinct epidemiology and resistance mechanisms affecting ceftolozane / tazobactam in Pseudomonas aeruginosa isolates recovered from ICU patients in Spain and Portugal depicted by WGS. J Antimicrob Chemother 1–10. https://​doi.​org/​10.​1093/​jac/​dkaa430
11.
go back to reference Hernández-García M, García-fernández S, García-castillo M, Melo-Cristino J, Pinto MF, Goncalves E et al (2020) Confronting ceftolozane-tazobactam susceptibility in multidrug-resistant Enterobacterales isolates and whole-genome sequencing results (STEP study). Int J Antimicrob Agents. https://doi.org/10.1016/j.ijantimicag.2020.106259 Hernández-García M, García-fernández S, García-castillo M, Melo-Cristino J, Pinto MF, Goncalves E et al (2020) Confronting ceftolozane-tazobactam susceptibility in multidrug-resistant Enterobacterales isolates and whole-genome sequencing results (STEP study). Int J Antimicrob Agents. https://​doi.​org/​10.​1016/​j.​ijantimicag.​2020.​106259
17.
go back to reference Karlowsky JA, Hackel MA, Wise MG, Six DA, Uehara T, Daigle DM et al (2023) In vitro activity of cefepime-taniborbactam and comparators against clinical isolates of gram-negative bacilli from 2018 to 2020: results from the Global Evaluation of Antimicrobial Resistance via Surveillance (GEARS) Program. Antimicrob Agents Chemother 1:67. https://doi.org/10.1128/aac.01281-22CrossRef Karlowsky JA, Hackel MA, Wise MG, Six DA, Uehara T, Daigle DM et al (2023) In vitro activity of cefepime-taniborbactam and comparators against clinical isolates of gram-negative bacilli from 2018 to 2020: results from the Global Evaluation of Antimicrobial Resistance via Surveillance (GEARS) Program. Antimicrob Agents Chemother 1:67. https://​doi.​org/​10.​1128/​aac.​01281-22CrossRef
18.
go back to reference Shields RK, Chen L, Cheng S, Chavda KD, Press EG (2016) Emergence of ceftazidime-avibactam resistance fue to plasmid-borne blaKPC-3 mutations during treatment of carbapenem-resistant Klebsiella pneumoniae infections. Antimicrob Agents Chemother 61:1–11. https://doi.org/10.1128/AAC.02097-16CrossRef Shields RK, Chen L, Cheng S, Chavda KD, Press EG (2016) Emergence of ceftazidime-avibactam resistance fue to plasmid-borne blaKPC-3 mutations during treatment of carbapenem-resistant Klebsiella pneumoniae infections. Antimicrob Agents Chemother 61:1–11. https://​doi.​org/​10.​1128/​AAC.​02097-16CrossRef
19.
go back to reference Bianco G, Boattini M, Comini S, Iannaccone M, Bondi A, Cavallo R et al (2022) In vitro activity of cefiderocol against ceftazidime-avibactam susceptible and resistant KPC-producing Enterobacterales: cross-resistance and synergistic effects. Eur J Clin Microbiol Infect Dis 1(41):63–70. https://doi.org/10.1007/s10096-021-04341-zCrossRef Bianco G, Boattini M, Comini S, Iannaccone M, Bondi A, Cavallo R et al (2022) In vitro activity of cefiderocol against ceftazidime-avibactam susceptible and resistant KPC-producing Enterobacterales: cross-resistance and synergistic effects. Eur J Clin Microbiol Infect Dis 1(41):63–70. https://​doi.​org/​10.​1007/​s10096-021-04341-zCrossRef
20.
go back to reference Daigle D, Hamrick J, Chatwin C, Kurepina N, Kreiswirth BN, Shields RK, Oliver A, Clancy CJ, Nguyen MH, Pevear D, Xerri L (2018) Cefepime/VNRX-5133 broad-spectrum activity is maintained against emerging KPC- and PDC-variants in multidrug-resistant K. pneumoniae and P. aeruginosa. Open Forum Infect Dis Ther 5(Suppl):1 Daigle D, Hamrick J, Chatwin C, Kurepina N, Kreiswirth BN, Shields RK, Oliver A, Clancy CJ, Nguyen MH, Pevear D, Xerri L (2018) Cefepime/VNRX-5133 broad-spectrum activity is maintained against emerging KPC- and PDC-variants in multidrug-resistant K. pneumoniae and P. aeruginosa. Open Forum Infect Dis Ther 5(Suppl):1
21.
go back to reference Castillo-Polo JA, Hernández-García M, Morosini MI, Pérez-Viso B, Soriano C, De Pablo R et al (2023) Outbreak by KPC-62-producing ST307 Klebsiella pneumoniae isolates resistant to ceftazidime/avibactam and cefiderocol in a university hospital in Madrid, Spain. J Antimicrob Chemother 25. https://doi.org/10.1093/jac/dkad086 Castillo-Polo JA, Hernández-García M, Morosini MI, Pérez-Viso B, Soriano C, De Pablo R et al (2023) Outbreak by KPC-62-producing ST307 Klebsiella pneumoniae isolates resistant to ceftazidime/avibactam and cefiderocol in a university hospital in Madrid, Spain. J Antimicrob Chemother 25. https://​doi.​org/​10.​1093/​jac/​dkad086
25.
go back to reference Wang X, Zhao C, Wang Q, Wang Z, Liang X, Zhang F et al (2020) In vitro activity of the novel β-lactamase inhibitor taniborbactam (VNRX-5133), in combination with cefepime or meropenem, against MDR Gram-negative bacterial isolates from China. J Antimicrob Chemother 1(75):1850–1858. https://doi.org/10.1093/jac/dkaa053CrossRef Wang X, Zhao C, Wang Q, Wang Z, Liang X, Zhang F et al (2020) In vitro activity of the novel β-lactamase inhibitor taniborbactam (VNRX-5133), in combination with cefepime or meropenem, against MDR Gram-negative bacterial isolates from China. J Antimicrob Chemother 1(75):1850–1858. https://​doi.​org/​10.​1093/​jac/​dkaa053CrossRef
26.
go back to reference Ranjitkar S, Reck F, Ke X, Zhu Q, McEnroe G, Lopez SL et al (2019) Identification of mutations in the mrdA gene encoding PBP2 that reduce carbapenem and diazabicyclooctane susceptibility of Escherichia coli clinical isolates with mutations in ftsI (PBP3) and which carry blaNDM-1. mSphere 28:4. https://doi.org/10.1128/msphere.00074-19CrossRef Ranjitkar S, Reck F, Ke X, Zhu Q, McEnroe G, Lopez SL et al (2019) Identification of mutations in the mrdA gene encoding PBP2 that reduce carbapenem and diazabicyclooctane susceptibility of Escherichia coli clinical isolates with mutations in ftsI (PBP3) and which carry blaNDM-1. mSphere 28:4. https://​doi.​org/​10.​1128/​msphere.​00074-19CrossRef
27.
go back to reference Vázquez-Ucha JC, Lasarte-Monterrubio C, Guijarro-Sánchez P, Oviaño M, Álvarez-Fraga L, Alonso-García I et al (2022) Assessment of activity and resistance mechanisms to cefepime in combination with the novel β-lactamase inhibitors zidebactam, taniborbactam, and enmetazobactam against a multicenter collection of carbapenemase-producing Enterobacterales. Antimicrob Agents Chemother 1:66. https://doi.org/10.1128/AAC.01676-21CrossRef Vázquez-Ucha JC, Lasarte-Monterrubio C, Guijarro-Sánchez P, Oviaño M, Álvarez-Fraga L, Alonso-García I et al (2022) Assessment of activity and resistance mechanisms to cefepime in combination with the novel β-lactamase inhibitors zidebactam, taniborbactam, and enmetazobactam against a multicenter collection of carbapenemase-producing Enterobacterales. Antimicrob Agents Chemother 1:66. https://​doi.​org/​10.​1128/​AAC.​01676-21CrossRef
28.
go back to reference Le Terrier C, Nordmann P, Sadek M, Poirel L (2023) In vitro activity of cefepime/zidebactam and cefepime/taniborbactam against aztreonam/avibactam-resistant NDM-like-producing Escherichia coli clinical isolates. J Antimicrob Chemother 1(78):1191–1194. https://doi.org/10.1093/jac/dkad061CrossRef Le Terrier C, Nordmann P, Sadek M, Poirel L (2023) In vitro activity of cefepime/zidebactam and cefepime/taniborbactam against aztreonam/avibactam-resistant NDM-like-producing Escherichia coli clinical isolates. J Antimicrob Chemother 1(78):1191–1194. https://​doi.​org/​10.​1093/​jac/​dkad061CrossRef
29.
go back to reference Golden AR, Baxter MR, Karlowsky JA, Mataseje L, Mulvey MR, Walkty A et al (2022) Activity of cefepime/taniborbactam and comparators against whole genome sequenced ertapenem-non-susceptible Enterobacterales clinical isolates: CANWARD 2007-19. JAC Antimicrob Resist 1:4. https://doi.org/10.1093/jacamr/dlab197CrossRef Golden AR, Baxter MR, Karlowsky JA, Mataseje L, Mulvey MR, Walkty A et al (2022) Activity of cefepime/taniborbactam and comparators against whole genome sequenced ertapenem-non-susceptible Enterobacterales clinical isolates: CANWARD 2007-19. JAC Antimicrob Resist 1:4. https://​doi.​org/​10.​1093/​jacamr/​dlab197CrossRef
30.
go back to reference Le Terrier C, Nordmann P, Freret C, Seigneur M, Poirel L (2023) Impact of acquired broad spectrum b-lactamases on susceptibility to novel combinations made of β-lactams (aztreonam, cefepime, meropenem, and imipenem) and novel β-lactamase inhibitors in Escherichia coli and Pseudomonas aeruginosa. Antimicrob Agents Chemother 1:67. https://doi.org/10.1128/aac.00339-23CrossRef Le Terrier C, Nordmann P, Freret C, Seigneur M, Poirel L (2023) Impact of acquired broad spectrum b-lactamases on susceptibility to novel combinations made of β-lactams (aztreonam, cefepime, meropenem, and imipenem) and novel β-lactamase inhibitors in Escherichia coli and Pseudomonas aeruginosa. Antimicrob Agents Chemother 1:67. https://​doi.​org/​10.​1128/​aac.​00339-23CrossRef
31.
go back to reference Lasarte-Monterrubio C, Fraile-Ribot PA, Vázquez-Ucha JC, Cabot G, Guijarro-Sánchez P, Alonso-García I et al (2022) Activity of cefiderocol, imipenem/relebactam, cefepime/taniborbactam and cefepime/zidebactam against ceftolozane/tazobactam- and ceftazidime/avibactam-resistant Pseudomonas aeruginosa. J Antimicrob Chemother 1(77):2809–2815. https://doi.org/10.1093/jac/dkac241CrossRef Lasarte-Monterrubio C, Fraile-Ribot PA, Vázquez-Ucha JC, Cabot G, Guijarro-Sánchez P, Alonso-García I et al (2022) Activity of cefiderocol, imipenem/relebactam, cefepime/taniborbactam and cefepime/zidebactam against ceftolozane/tazobactam- and ceftazidime/avibactam-resistant Pseudomonas aeruginosa. J Antimicrob Chemother 1(77):2809–2815. https://​doi.​org/​10.​1093/​jac/​dkac241CrossRef
32.
go back to reference Pérez-Vázquez M, Sola-Campoy PJ, Zurita ÁM, Ávila A, Gómez-Bertomeu F, Solís S et al (2020) Carbapenemase-producing Pseudomonas aeruginosa in Spain: interregional dissemination of the high-risk clones ST175 and ST244 carrying blaVIM-2, blaVIM-1, blaIMP-8, blaVIM-20 and blaKPC-2. Int J Antimicrob Agents 1(56). https://doi.org/10.1016/j.ijantimicag.2020.106026 Pérez-Vázquez M, Sola-Campoy PJ, Zurita ÁM, Ávila A, Gómez-Bertomeu F, Solís S et al (2020) Carbapenemase-producing Pseudomonas aeruginosa in Spain: interregional dissemination of the high-risk clones ST175 and ST244 carrying blaVIM-2, blaVIM-1, blaIMP-8, blaVIM-20 and blaKPC-2. Int J Antimicrob Agents 1(56). https://​doi.​org/​10.​1016/​j.​ijantimicag.​2020.​106026
33.
go back to reference Hernández-García M, García-Castillo M, Melo-Cristino J, Pinto MF, Gonçalves E, Alves V et al (2022) In vitro activity of imipenem/relebactam against Pseudomonas aeruginosa isolates recovered from ICU patients in Spain and Portugal (SUPERIOR and STEP studies). J Antimicrob Chemother 1(77):3163–3172. https://doi.org/10.1093/jac/dkac298CrossRef Hernández-García M, García-Castillo M, Melo-Cristino J, Pinto MF, Gonçalves E, Alves V et al (2022) In vitro activity of imipenem/relebactam against Pseudomonas aeruginosa isolates recovered from ICU patients in Spain and Portugal (SUPERIOR and STEP studies). J Antimicrob Chemother 1(77):3163–3172. https://​doi.​org/​10.​1093/​jac/​dkac298CrossRef
Metadata
Title
Deciphering mechanisms affecting cefepime-taniborbactam in vitro activity in carbapenemase-producing Enterobacterales and carbapenem-resistant Pseudomonas spp. isolates recovered during a surveillance study in Spain
Authors
Marta Hernández-García
María García-Castillo
Marta Nieto-Torres
Germán Bou
Alain Ocampo-Sosa
Cristina Pitart
Irene Gracia-Ahufinger
Xavier Mulet
Álvaro Pascual
Nuria Tormo
Antonio Oliver
Patricia Ruiz-Garbajosa
Rafael Cantón
Publication date
02-12-2023
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Clinical Microbiology & Infectious Diseases / Issue 2/2024
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-023-04697-4

Other articles of this Issue 2/2024

European Journal of Clinical Microbiology & Infectious Diseases 2/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.